Certificate

Brand

Panagene

Product Type

Reagents

Highlights

Detecting 43 mutations on codons 2, 3, 4 of the NRAS gene

 

Code: PNAC-1101 (43 mutations)

Packing: 25 tests/set

Certificate: CE-IVD

Application

▶ Application of the kit

Detection ability: Detecting 43 mutations on codons 2, 3, 4 of the NRAS gene
High sensitivity and specificity even for small amounts of DNA (detects 2% mutation concentration with 10ng DNA sample)

Specifications

▶ Technology used:

Based on PNA-mediated Real-time PCR clamping technology using optimally designed PNA probes that adhere to the wild-type DNA template (DNA does not contain mutations).

▶ Input sample source: surgical tissue, FFPE sample

▶ Compatible systems: Biorad cfx 96, Light cycler 480, ABI 7500/7900, StepOnePlus, Rotor-Gene Q

▶ Certificate: CE-IVD Certified for Medical Diagnostic Use

 

Other information

Supplier

Panagene

Related Products

EntroGen NGS Targeted Hotspot Panel

The EntroGen NGS Targeted Hotspot Panel is a comprehensive assay that detects clinically relevant mutations in solid tumors using next-generation sequencing, compatible with fresh frozen and FFPE samples. It offers high sensitivity, low DNA input, and the ability to batch up to 12 samples in a single run, making it ideal for labs with limited sample volumes.

EntroGen’s BRCA Complete™ Expanded Panel

EntroGen’s BRCA Complete™ Expanded Panel is a comprehensive NGS solution that detects both germline and somatic mutations in genes like BRCA1, BRCA2, CHEK2, PALB2, RAD51C, and TP53 with high sensitivity and specificity. Compatible with blood, fresh frozen, and FFPE samples, the panel reduces allele dropouts and off-target reads using a tiled amplicon PCR approach. It includes reagents for library preparation and user-friendly software for easy mutation identification, along with quality control assays to ensure high-quality data without repeat sequencing.

NgeneBio – SOLIDaccuTest™

SOLIDaccuTest™ is an excellent tool for discovering variants associated with solid tumors using a comprehensive approach to next-generation sequencing (NGS). It reflects the latest research trends and is optimized for medical purposes by selecting essential genes of solid tumors including lung, colon, breast, skin brain, stomach and ovarian cancers, etc.

BRCAaccuTest™ & BRCAaccuTest™PLUS

BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test

BRCAaccuTest™ & BRCAaccuTest™PLUS

BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.

Next Generation Sequencing System – NovaSeq 6000

Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time

PANARealTyperTM HPV Kit

PANA RealTyperTM HPV Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.

DxFLEX

DxFLEX is a new clinical flow cytometry platform derived from the successful CytoFLEX. The advanced sensitivity and intuitive software DxFLEX makes flow cytometry routine for both novice and expert flow cytometry technicians and promotes standardization. Functionality in the autoloader facilitates accurate results and sample tracking.

 

TruSight® Tumor 26

TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants

TruSight Cancer Sequencing Panel

Developed with cancer genomics experts in collaboration, oligos ready-to-use, pre-engineered oligos allow researchers to sequence a wide range of genes and single nucleotide polymorphisms (SNPs) in advance. this is related to cancer predisposition